Updated clinical data from a phase Ib combination cohort evaluating vepdegestrant, an investigational oral proteolysis targeting chimera estrogen receptor degrader, in combination with palbociclib (Ibrance) are consistent with data presented at the San Antonio Breast Cancer Symposium in December 2023.
Nearly two years after FDA issued a final rule requiring radiologists to tell women whether their breasts are “dense” or “not dense” after a mammogram, the notification has become nearly universal.
